chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Itching on side of both knees has occurred each of the 3 nights since the day of the vaccine
Pt received 4 doses of Hepatitis B vax, 2 doses were /w  Recombivax & 2 doses /w Engerix B vax, Vaccinee was found to be a non responder
G40.909 EPILEPSY, UNSPECIFIED 10/1/2021 MODERATE DEHYDRATION
Patient reported fever (patient does not know temp) and body aches. She is taking ibuprofen for fever.
Fever 3/3, 3/4 (103/5), 3/5 (100.3); given TYLENOL. Seen in office 3/5, temp 101. Dx w/acute otitis media-put on amoxicillin. Pt. very fussy, and not eating well. 3/7 went to ER, still not eating well, less wet diapers, and very fussy-course with eating. Xray completed showed possible ileus. Follow up appt. 3/9-slight improvement in sx.
Child had immunizations Friday 5/27/16, returned to office Tues. 5/31/16 with a rash that started that a.m. very suddenly. The macular rash was located on the scalp, face, upper back, lower leg and left arm. She also had a fever of 103 degrees.
Pt was vaccinated on 9/18/12 with FLUVIRIN (had flu vaccines in the past with no reactions) and developed slight swelling of lower lips at home. Pt took BENADRYL and after 4 hours it went away.
2 strokes in occipital lobe and dissection of artery; 2 strokes in occipital lobe and dissection of artery; This is a spontaneous report from a contactable consumer (patient) A 49-year-old female patient (not pregnant) received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Lot Number: EN6208) via an unspecified route of administration in Arm Left on 2021 as single dose for covid-19 immunisation.  Medical history included lupus, aplastic anemia (apls) and Raynauds; patient had unspecified allergies. Previously on 09Mar2021 (at 49 years) the patient took the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Lot Number: En6203) in Right arm for covid-19 immunisation.Concomitant medications included hydroxychloroquine; escitalopram oxalate (LEXAPRO); rivaroxaban (XARELTO) and vitamis, all taken for unspecified indication, start and stop date were not reported. Nasal Swab on 02Sep2021 was negative. The patient experienced 2 strokes in occipital lobe and dissection of artery on 07Aug2021 at 08:00 am. Patient was treated with Lovenox.Events results in Emergency room/department or urgent care and hospitalization for 4 days in Aug2021.Patient recovered with lasting effects on an unknown date in 2021.
Upper arm swelling; High fever; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (Upper arm swelling) and PYREXIA (High fever) in a female patient of an unknown age who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On 25-May-2023, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PERIPHERAL SWELLING (Upper arm swelling) and PYREXIA (High fever). At the time of the report, PERIPHERAL SWELLING (Upper arm swelling) and PYREXIA (High fever) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: High fever.         Concomitant medications were not reported.  It was unknown if the patient experienced any additional symptoms/events.  Treatment information was not reported.
Kinrix given to a 5-month-old; Kinrix was 2nd dose of dtap and ipv; This case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 5-month-old male patient who received DTPa-IPV (Kinrix) (batch number G9N2M, expiry date 14th April 2024) for prophylaxis.   Co-suspect products included dtpa-ipv vaccine pre-filled syringe device (Kinrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 20th February 2023, the patient received Kinrix and Kinrix Pre-Filled Syringe Device. On 20th February 2023, unknown after receiving Kinrix and Kinrix Pre-Filled Syringe Device, the patient experienced inappropriate age at vaccine administration and inappropriate schedule of vaccine administered. On an unknown date, the outcome of the inappropriate age at vaccine administration and inappropriate schedule of vaccine administered were unknown.     This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 1-Mar-2023 Reporter's Comments:  A clinic manager reported that a 5-month-old male patient received a dose of Kinrix on 20th February 2023.  No symptoms reported. Health care professional (HCP) reported, to the 2nd line agent, that Kinrix was patients 2nd dose of dtap and ipv and HCP was not sure what the intention was to give or timing of previous doses. The reporter consented to follow up via email. Additional Supportive Information: the patient received Kinrix as 2nd dose of Dtap and IPV vaccine, which led to inappropriate age at vaccine administration, inappropriate schedule of vaccine administered.
WOKE IN THE MORNING WITH SWELLING, REDNESS, AND TENDERNESS IN RIGHT UPPER ARM. HAD SOME TENDERNESS IN LYMPHNODES.  TOOK TYLENOL.
This spontaneous report as received from a other health professional refers to a patient of unknown age. On an unknown date the patient was vaccinated with ZOSTAVAX for prophylaxis. Concomitant therapies included sterile diluent (MERCK). On an unknown date the patient experienced incorrect product storage and no adverse event. The outcome of incorrect product storage and no adverse event is unknown. The reporter considered incorrect product storage and no adverse event to be not related to ZOSTAVAX. Sender's Comments: US-009507513-1708USA013519: US-009507513-1708USA013488: US-009507513-1708USA013516: US-009507513-1708USA013517.
Rash lower underside of arm, not at site of injection no vesicles-may not be related.
small rash on back; This case was reported by a pharmacist via call center representative and described the occurrence of rash in a 65-year-old female patient who received Herpes zoster (Shingrix) (batch number CF9K4, expiry date 11th September 2021) for prophylaxis.   On 24th May 2019, the patient received the 1st dose of Shingrix (intramuscular). On 25th May 2019, 1 days after receiving Shingrix, the patient experienced rash. On an unknown date, the outcome of the rash was recovered/resolved.   It was unknown if the reporter considered the rash to be related to Shingrix.  Additional details were provided as follows: The patient received dose of Shingrix in the right arm. After vaccination, the patient experienced rash on back. The patient consented to follow up. This case has been linked with case US2019AMR138425, reported by same reporter.
I developed pain a few hours after receiving my vaccine. The pharmacist administered the vaccine very high up in the shoulder. The pain and discomfort continued and got worse over the weekend. I went to my doctor the following Monday who, in her notes described, "inappropriate administration of the vaccine and the patient developed subdeltoid bursitis in the right shoulder." Prior to my doctor visit, I was taking Tylenol for the pain. My doctor prescribed topical Lidocaine patches. From there, the pain began to improve and by the following Friday, the pain was gone.
Initial information received on 21-Aug-2018 regarding an unsolicited valid non-serious case received from a nurse. This case involves a four months old male patient who received a liquid portion without the ACTHIB component, while he received vaccine PENTACEL (lot number: C5550AA, expiry date: 10-Oct-2019) in right leg. The patient's past vaccination(s) included first dose of PENTACEL. he patient's past medical history, medical treatment(s) and family history were not provided. It was a case of actual medication error due to inappropriate reconstitution technique. It was reported that initial dose given was liquid portion only without ACTHIB component, in right leg. Second dose was given with full PENTACEL dose with both components mixed and also given in right leg. Liquid component: Lot: C5409AA, Exp: 10-Oct-2019, ACTHIB component: Lot: C5550AA, Exp 10-Oct-2019. It was unknown if any adverse event was occurred. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive and Module VI of the Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error. Documents held by sender: none.
Patient reports her left arm feels very heavy and numb (arm she got vaccine) no other symptom. BP 135/80, pulse 68, Spo2 96%. Cleared by EMS
The 2nd day after the injection, I got severe tinnitus.  I've had tinnitus before this for a couple years, but it was at a minimum very tolerable level until the covid shot.  It's been 2 weeks and it's very difficult to sleep because of the unbearable increase in loudness in my tinnitus since the 2nd day of my shot.  I got a hearing test this week (Friday Feb 19th) and my audiologist said I had NO loss of hearing from the shot.
Headache; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (Headache) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030220A) for COVID-19 vaccination.     Concurrent medical conditions included Type 2 diabetes mellitus. Concomitant products included INSULIN for an unknown indication.   On 22-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Mar-2021, the patient experienced HEADACHE (Headache). The patient was treated with PARACETAMOL (TYLENOL) for Headache, at a dose of 1 dosage form. At the time of the report, HEADACHE (Headache) outcome was unknown. Not Provided          Patient was taking blood pressure pills,cholesterol pills,type 2 diabetes pills as concomitant medication. Action taken for Moderna COVID-19 Vaccine was not applicable.
both Shingrix shots and have had two very light cases/ Suspected vaccination failure; had two very light cases since; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingrix) for prophylaxis.  Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.  The patient's past medical history included shingles.  On an unknown date, the patient received the 2nd dose of Shingrix and the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix and Shingrix, the patient experienced vaccination failure (Verbatim: both Shingrix shots and have had two very light cases/ Suspected vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: had two very light cases since). The outcome of the vaccination failure was unknown and the outcome of the shingles was not reported.  It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix and Shingrix.  It was unknown if the company considered the vaccination failure and shingles to be related to Shingrix and Shingrix.  Additional Information: GSK Receipt Date: 22-APR-2023 This case was reported by the patient via interactive digital media. The reporter stated that he/she had Shingles then had both Shingrix shots and have had two very light cases (Shingles) since. This case was considered as suspected vaccination failure as details regarding, time to onset for shingles and laboratory confirmation regarding shingles were unknown at the time of reporting. Follow-up would not possible, as no contact, details were available.
Headache started late the same day as the vaccine, on and off for next 2 days.  Ibuprofen taken for headaches on 12/19 and 12/20. Fever started the next day 12/20.  Subsided on 12/21.  Ibuprofen taken 12/19 and 12/20.  Highest fever was 100 deg F. Fatigue started the next day 12/20, subsided on 12/22.  Was the worst on 12/21.
Feeling tired, body aches, sinus drainage, sneezing, coughing, low grade temperature  Treatment: Vitamin C/D, Zinc, cough medicine.
Adult patient here for second dose of Hepatitis B series. Patient was given 0.5 ml of Pediatric Hepatitis B vaccine by RN. The nurse called the Immunization Program as soon as she realized the error and was instructed to give a second dose of 0.5 ml Pediatric Hepatitis B vaccine that day. If the second half of the dose could be given on the same day as the first half, the vaccine would be counted as valid. The patient was called and informed of the error, and RN vaccinated him on the same day with the second half dose. Patient did not experience any adverse reactions.
I experienced the following day, I started getting very bad chest tightening and felt like spasms. I was not sure if I was having a heart attack, like a gripping pain in my chest, lasted for 1-2 hours. In the meantime, I did go to the ER because I thought I was having a heart attack.  EKG and x-ray of the chest was performed, lab work was also performed. My BP went way up as well and I felt very nervous. I also saw a cardiologist for the chest tightening sensation.  I think that the J&J vaccine I received was related to my symptoms.  I can say today I sometime experience chest tightness but very lightly and at this time I have no symptoms.   I do not have my lot# at this time to provide.
This spontaneous report was received from a pharmacist refers to a 60 year old male patient. Medical history was not reported. On 15-NOV-2014 the patient was vaccinated with ZOSTAVAX single dose, subcutaneous in the right arm, lot # K009199, expiration date: 27-SEP-2015. Concomitant therapy was not reported. The pharmacist informed that on 16-NOV-2014 the patient developed a 3-4 inch painful area of redness and warmth at the injection site. The pharmacist suggested the patient to apply cool compress to the area of reaction and to take ibuprofen as needed for pain. The pharmacist was requesting a lot check. There were not laboratories diagnostics performed. The patient's wife sought medical attention speaking with the pharmacist. Additional information has been requested.
pain at injection site occurred an hour after injection and persisted into next day and continued to increase in pain and becoming tender to touch and movement.  Muscle soreness throughout body, joint pain throughout body, chills and fatigue occurred previous day and continually persisted
Rash erythematous, Headache, Pyrexia. A nurse reported the occurrence of a rash in an 11-year-old male who was vaccinated with hepatitis A vaccine inactivated (Havrix) for prophylaxis. The subject's medical history, concurrent conditions, and concurrent medications were not reported. On 04 March 2003, the subject received an injection of Havrix. Later that day, he developed a rash, headache and fever. He was seen by the reporter on 07 March 2003. She noted that the rash was erythematous with demarcated edges and covered an area measuring 5cm by 5cm. The location of the rash was not specified. The subject reported that the rash had gotten bigger over time. The nurse also noted an oral temperature of 99.8 degrees Fahrenheit. The Havrix immunization series was discontinued.
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 67-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 019B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 30-Mar-2021 at 11:26 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 30-Mar-2021 at 11:26 AM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). In 2021, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Age of patient was reported as 67.65 for dose administered on 30-Mar-2021  No concomitant medications were reported. Batch number 019B21A underwent temperature excursion on 30-Mar-2021 with temperature 33 degrees Fahrenheit from 11:00 AM to 12 :00 PM. This vial was moved to fridge on 23-Mar-2021 and beyond use date for the vial was reported as 22-Apr-2021. Product moved to clinic on 30-Mar-2021. Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration. Vaccines were not frozen at time of administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. Temperature recordings were taken using a Fisher brand traceable temperature monitor at every hour. No treatment medications were reported.   This case was linked to MOD-2022-566976 (Patient Link).
Raised, itchy rash on injection arm wrist, same rash across mid torso- appeared approximately 10 days after first shot.
Pt vaccinated with OPV/DTP/MMR developed extreme fussiness, screaming from Fri no 26OCT90 day of immunization to Sunday PM 28OCT90 "burning with fever" Tylenol helped if given q 4hrs.
Around 4 hours after the vaccine, I got minor head pressure and a little nausea. Around 12 hours after the vaccine, I woke up with head pain that escalated very quickly. It was some of the worst pain I have ever had next to childbirth. My entire head, temples, forehead, and back of neck had excruciating pain and felt like the skin was on fire. It wasn?t hot to touch but to me it felt like my skin was burning only from my neck up. I had a fever of 101. I used ice packs directly to my head and neck and Tylenol. Neither took the pain away. This all lasted 15 hours. The fever broke and the pain went away. The next morning, about 40 hours after the vaccine, my entire neck and spine wore sore and I was achy. This lasted the whole day. I have had periods through the next couple days where I have brief moments of feeling hot.  I also developed 2 small bruises (one on each leg), but neither are painful. Today I have had mouth sores/irritation but by evening that went away.
This spontaneous report as received from a pharmacist refers to a female patient of unknown age with codeine allergy and sulfa allergy. The patient's pertinent medical history was not reported. On 14-OCT-2014 the patient was vaccinated with PNEUMOVAX 23 (lot # K007824 and expiry date 05-NOV-2015), 0.5 ml, intramuscular. Other suspect therapies included FLUZONE (high dose). On an unknown date the patient experienced severe reaction with erythema and swelling of the upper arm after receiving PNEUMOVAX 23 and FLUZONE (high dose) in the same arm. The outcome of swelling of the upper arm after receiving PNEUMOVAX 23 and severe reaction with erythema and swelling of the upper arm after receiving PNEUMOVAX 23 and FLUZONE (high dose) in the same arm. The outcome of swelling of the upper arm after receiving PNEUMOVAX 23 and severe reaction with erythema was unknown. Causality was unspecified by the reporter. This is one of the several reports received from the same reporter (MARRS # 1410USA007922, 1410USA012696, 1410USA012695 and 1410USA015698). Additional information has been requested.
red, warm area (about 3 x 4 inches) around the injection site, with some itching and soreness
2 hours after administration of influenza vaccine, patient developed diffuse rash across chest. Later broke out in forearm of same arm as vaccine site.
1 hour after administration of MCV4 (Menomune) - pt developed urticarial rash on whole body. Resolved with medical treatment.
tested positive/ Not knowing I was already affected, I took the second shot; tested positive/ Not knowing I was already affected, I took the second shot; This is a s spontaneous report from a contactable consumer (patient).  A patient of unspecified age and gender received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 1 on an unspecified date and dose 2 on 28Feb2021 via an unspecified route of administration (Batch/Lot number was not reported) as single dose for covid-19 immunisation. The patient's medical history and concomitant medications were not reported.  Patient was tested positive on 01Mar2021. He/she took the second shot of vaccine yesterday but already develop symptoms of dry cough that started 27Feb2021 Saturday. Patient was not knowing he/she was already affected, he/she took the second shot. With no fever but mild dry cough on day 3, patient thought it was working.  Outcome of events was unknown.   Information about lot/batch number has been requested.
Patient started to stutter about 1 wk after receiving nasal H1N1 vaccine #1. Mom said he is starting speech therapy.
Full body hives that appeared to go dormant every hour or so and then show up in another place. The last two days they have stayed along hair line, on palms, elbows, top of the hands and bikini line.
Headache, body ache, joint pain, extreme fatigue, cramping, cold sweats. All started around 17 hours after vaccination.
Expired vaccine used; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) in a 32-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 10-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used). On 10-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant medications were reported No Treatment medications were reported